With a fresh $75M, Michael Ehler­s' lat­est take on non-vi­ral gene ther­a­py is ready for take­off

When Michael Ehlers hit the ex­it at Bio­gen a few years ago to be­come a ven­ture part­ner at ATP, he al­so took the lead at a gene ther­a­py start­up called Lime­light Bio. Like many oth­ers in pur­suit of gene ther­a­py 2.0, the com­pa­ny was work­ing on non-vi­ral de­liv­ery ap­proach­es. And one pi­lot pro­gram re­al­ly stuck with him.

The sci­en­tists won­dered whether they could make a ful­ly syn­thet­ic DNA that would have “all the ver­sa­til­i­ty of not be­ing a vi­ral-based DNA,” but with su­pe­ri­or prop­er­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER